Is Europe’s BeNeLuxA Coalition Moving Too Fast?
The BeNeLuxA initiative for improving access to medicines could soon include more countries, but much about the collaboration remains opaque for the pharmaceutical industry. Lawyer Koosje van Lessen Kloeke says constructive dialogue between the initiative and industry would benefit the collaboration.
You may also be interested in...
The BeNeLuxA coalition shows that “resetting the balance of power” is possible to give governments more clout in pricing negotiations, says the European Public Health Alliance.
An initiative from the Netherlands to ensure that pharmaceutical companies market centrally approved medicines in all EU member states is probably intended to fuel discussions on the differences in national pricing and reimbursement policies, says a legal expert.
In a wide-ranging discussion at the recent European Health Forum Gastein, policy makers explored big-picture challenges and ideas of what governments should do to ensure access to increasingly expensive medicines as pressures grow on national health care systems.